Table 7. Comparison of qRT-PCR and microarray analysis of select genes, with direction of change denoting change in group with neurocognitive impairment.
| Gene Symbol | Gene Name | Fold change qRT-PCR a | P-value qRT-PCR | Fold change microarray a | P-value microarray |
|---|---|---|---|---|---|
| HAND1 | heart and neural crest derivatives expressed 1 | -5.18 | 0.000 | -1.95 | 0.021 |
| SPRED1 | sprouty-related, EVH1 domain containing 1 | 1.81 | 0.001 | 1.62 | 0.024 |
| LGMN | Legumain | 2.00 | 0.001 | 1.81 | 0.010 |
| ADAMTS9 | ADAM metallopeptidase with thrombospondin type 1 motif, 9 | 2.79 | 0.001 | 1.60 | 0.010 |
| NRP1 | neuropilin 1 | 2.09 | 0.002 | 1.61 | 0.019 |
| VSIG4 | V-set and immunoglobulin domain containing 4 | 2.27 | 0.003 | 1.60 | 0.002 |
| ALDH1A3 | aldehyde dehydrogenase 1 family, member A3 | 2.17 | 0.003 | 2.11 | 0.027 |
| CD163 | CD163 molecule | 2.28 | 0.003 | 1.85 | 0.017 |
| ANGPT2 | angiopoietin 2 | 3.02 | 0.006 | 1.71 | 0.032 |
| CD34 | CD34 molecule | 3.83 | 0.007 | 1.53 | 0.018 |
| OSR1 | odd-skipped related 1 (Drosophila) | -2.90 | 0.007 | -1.54 | 0.043 |
| PECAM1 | platelet/endothelial cell adhesion molecule 1 | 1.78 | 0.009 | 1.51 | 0.006 |
| CTSB | cathepsin B | 1.48 | 0.009 | 1.69 | 0.012 |
| WSB1 | WD repeat and SOCS box containing 1 | -1.41 | 0.009 | -1.53 | 0.002 |
| UCP2 | uncoupling protein 2 (mitochondrial, proton carrier) | 1.71 | 0.010 | 1.50 | 0.012 |
| SEPP1 | selenoprotein P, plasma, 1 | 2.49 | 0.010 | 2.58 | 0.009 |
| LDHB | lactate dehydrogenase B | 1.69 | 0.011 | 1.64 | 0.007 |
| SLCO2B1 | solute carrier organic anion transporter family, member 2B1 | 2.30 | 0.011 | 1.61 | 0.014 |
| LY6G6C | lymphocyte antigen 6 complex, locus G6C | -2.52 | 0.012 | -1.34 | 0.058 |
| VWF | von Willebrand factor | 3.52 | 0.013 | 2.35 | 0.047 |
| VCAN | versican | 1.69 | 0.013 | 1.61 | 0.031 |
| COLEC12 | collectin sub-family member 12 | 1.89 | 0.015 | 1.77 | 0.014 |
| LIPA | lipase A, lysosomal acid, cholesterol esterase | 1.71 | 0.016 | 1.63 | 0.025 |
| CXCL12 | chemokine (C-X-C motif) ligand 12 | 2.83 | 0.017 | 1.54 | 0.019 |
| APOE | apolipoprotein E | 2.54 | 0.017 | 2.46 | 0.056 |
| GPD1L | glycerol-3-phosphate dehydrogenase 1-like | 1.85 | 0.018 | 1.54 | 0.013 |
| MS4A6A | membrane-spanning 4-domains, subfamily A, member 6A | 1.82 | 0.019 | 1.79 | 0.006 |
| CSF1R | colony stimulating factor 1 receptor | 1.71 | 0.019 | 1.71 | 0.023 |
| MMRN1 | multimerin 1 | 3.79 | 0.021 | 1.62 | 0.020 |
| LYVE1 | lymphatic vessel endothelial hyaluronan receptor 1 | 2.03 | 0.021 | 1.59 | 0.024 |
| RDH11 | retinol dehydrogenase 11 (all-trans/9-cis/11-cis) | 1.30 | 0.023 | 1.52 | 0.001 |
| PDGFRA | platelet-derived growth factor receptor, alpha polypeptide | 1.82 | 0.023 | 1.63 | 0.029 |
| OLFML2B | olfactomedin-like 2B | 2.07 | 0.023 | 1.63 | 0.005 |
| PDGFRB | platelet-derived growth factor receptor, beta polypeptide | 1.97 | 0.026 | 1.97 | 0.039 |
| DAB2 | disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) | 1.52 | 0.029 | 1.78 | 0.015 |
| C1orf54 | chromosome 1 open reading frame 54 | 1.63 | 0.029 | 1.72 | 0.016 |
| STX4 | syntaxin 4 | -1.43 | 0.029 | -1.54 | 0.023 |
| FAM69A | family with sequence similarity 69, member A | 1.99 | 0.029 | 1.59 | 0.030 |
| CHI3L2 | chitinase 3-like 2 | 1.72 | 0.032 | 1.83 | 0.057 |
| PROCR | protein C receptor, endothelial | 1.80 | 0.034 | 1.54 | 0.042 |
| MAOA | monoamine oxidase A | 1.44 | 0.037 | 1.71 | 0.031 |
| DARC | Duffy blood group, chemokine receptor | 2.82 | 0.037 | 1.74 | 0.029 |
| FBLN1 | fibulin 1 | 1.95 | 0.041 | 1.91 | 0.024 |
| CDH11 | cadherin 11, type 2, OB-cadherin (osteoblast) | 1.74 | 0.044 | 2.02 | 0.026 |
| NEDD9 | neural precursor cell expressed, developmentally down-regulated 9 | -1.45 | 0.044 | -1.54 | 0.022 |
| OXSR1 | oxidative-stress responsive 1 | -1.39 | 0.046 | -1.54 | 0.026 |
| ESAM | endothelial cell adhesion molecule | 1.82 | 0.047 | 1.81 | 0.025 |
| EDN1 | endothelin 1 | -1.57 | 0.049 | -1.82 | 0.044 |
a Fold change- the number of times the average expression level in the chorioamniotic membranes of the neurocognitive impairment group differs from the average expression level in the normal comparison group; positive values (no sign) denote increased expression (up-regulation) in the neurocognitive impairment group, and negative values (minus sign) indicate decreased expression (down-regulation) in the neurocognitive impairment group.